


## Irreversible Inhibition of DNA Polymerase $\beta$ by an Oxidized Abasic Lesion

Lirui Guan and Marc M. Greenberg\*

Department of Chemistry, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218


Received February 16, 2010; E-mail: mgreenberg@jhu.edu

DNA oxidation is a source of carcinogenicity. It is also the source of the cytotoxicity of  $\gamma$ -radiolysis and antitumor agents, such as the enediynes. Double-strand breaks (dsbs) are often considered to be an extremely challenging form of DNA damage for cells to overcome. However, few damaging agents produce dsbs in high yields.<sup>1</sup> In contrast, oxidized abasic lesions [e.g., 2-deoxyribonolactone (L), C4-AP, dioxobutane (DOB)] resulting from hydrogen atom abstraction from the 2'-deoxyribose ring are produced in greater yields by a variety of DNA-damaging agents.<sup>2</sup> These lesions exhibit potentially important reactivity and effects on repair enzymes. For instance, L cross-links base-excision repair (BER) enzymes, while C4-AP and DOB form DNA interstrand cross-links.<sup>3–6</sup> Furthermore, a cross-link involving C4-AP is converted into a dsb by a bacterial nucleotide excision repair system.<sup>7</sup> We report here that the DOB lesion efficiently and irreversibly inhibits repair by DNA polymerase  $\beta$  (Pol  $\beta$ ).



The DOB lesion is produced concomitantly with a strand break following C5'-hydrogen atom abstraction (Scheme 1).<sup>8</sup> It has been detected in DNA exposed to antitumor agents as well as ionizing radiation and accounts for ~5% of the deoxyribose oxidation products from the latter.<sup>9</sup> DOB undergoes elimination to produce 5'-dRP, which reacts to yield likely promutagenic exocyclic adducts with dC and dA.<sup>10</sup> DOB also yields DNA interstrand cross-links by reacting selectively with dA opposite a 3'-adjacent thymidine.<sup>5</sup> In view of the potential detrimental effects of these secondary products, efficient repair of DOB should be important.




### Scheme 1




Abasic sites (APs) are typically removed by a series of enzymes in the BER pathway (Scheme 2). In mammalian cells, the 5'-dRP lesion is excised by Pol  $\beta$  following AP incision at its 5'-phosphate by apurinic endonuclease (Ape1).<sup>11,12</sup> Excision is achieved via a lyase mechanism in which Pol  $\beta$  forms an intermediate Schiff base with the 5'-dRP intermediate.<sup>13</sup> Pol  $\beta$  then fills the gap using an appropriate dNTP, and repair is completed by an ATP-dependent DNA ligase. Following this paradigm, we expected that Pol  $\beta$  excision would be the first step

in BER of DOB because its formation in conjunction with a direct strand break obviates the need for Ape1.

### Scheme 2




DOB excision by Pol  $\beta$  was examined using the ternary complex **1**, in which the oligonucleotide containing the lesion was prepared via solid-phase synthesis as previously reported.<sup>14</sup> Subjection of 3'-<sup>32</sup>P-**1** (200 nM; the strand containing DOB is labeled) to Pol  $\beta$  (5 nM) rapidly produced a small amount of the expected oligonucleotide product, but the reaction stopped after a few minutes (Figure 1A). Additional aliquots of Pol  $\beta$  yielded the same observation. Approximately 4 equiv of product was produced from each aliquot of enzyme. In contrast, a comparable substrate containing 5'-dRP (3'-<sup>32</sup>P-**2**; the strand containing dRP is labeled) was completely consumed by Pol  $\beta$  when the substrate was present in 40-fold excess.<sup>15</sup> These observations suggested that Pol  $\beta$  was inhibited by DOB-containing DNA. Additional evidence for inhibition by DOB was gleaned by preincubating Pol  $\beta$  for 3 min (the amount of time to inactivate Pol  $\beta$  in Figure 1A) with various concentrations of **1** prior to adding the enzyme to 3'-<sup>32</sup>P-**2** and measuring the amount of product produced over 10 min at 37 °C (Figure 1B). Inhibition depended upon the concentration of **1**, and the median inhibitory concentration (IC<sub>50</sub>) was 2.8 ± 0.3 nM in the presence of 2.5 nM Pol  $\beta$ .




**Figure 1.** Inhibition of Pol  $\beta$  lyase reaction by DOB. (A) Amount of product obtained from 3'-<sup>32</sup>P-**1** (200 nM) upon addition of Pol  $\beta$ . Each arrow indicates the addition of 1 pmol of Pol  $\beta$ . (B) Fraction of 5'-dRP (3'-<sup>32</sup>P-**2**, 100 nM) converted following preincubation with DOB-containing DNA **1**.

The rapid conversion of a small number of equivalents of 3'-<sup>32</sup>P-1 and the abrupt cessation of the reaction suggested that DOB irreversibly inhibited Pol β. Evidence for this mode of inhibition was obtained kinetically (Figure 2).<sup>15,16</sup> The ratio of product produced from 3'-<sup>32</sup>P-2 (5'-dRP) in the presence of inhibitor relative to that formed in the absence of DOB was measured as a function of time for a series of inhibitor (1) concentrations (0–60 nM). A plot of the logarithm of the relative activities decayed linearly as a function of time (Figure 2A), and the pace at which inactivation occurred was proportional to the concentration of 1. The  $K_I$  ( $12.8 \pm 5.2$  nM) and  $k_{\text{inact}}$  [ $(4.2 \pm 0.9) \times 10^{-4} \text{ s}^{-1}$ ] values were subsequently determined by plotting the half-life for inactivation versus the reciprocal of the concentration of 1 (DOB) (Figure 2B). Irreversible inhibition of Pol β by DOB is more efficient than that by 2-deoxyribonolactone (L), which cross-links Pol β following Apε1 incision, presumably because of the greater electrophilicity of the aldehyde groups in the former.<sup>3,17</sup>




**Figure 2.** Kinetic analysis of irreversible inhibition by DOB-containing DNA 1. (A) Effect of increasing [DOB] on Pol β (7.5 nM) lyase reaction of AP (3'-<sup>32</sup>P-2, 500 nM). (B) Half-life of Pol β inactivation as a function of [DOB].

### Scheme 3



Two modes of irreversible inhibition of Pol β by DOB were envisioned. The DOB lesion could inactivate Pol β by trapping the nucleophilic lysine involved in Schiff base formation and/or the butenedial product could react with the enzyme. (Scheme 3 shows examples of possible products.) Attempts to isolate DNA–protein cross-linked product(s) by gel electrophoresis were unsuccessful. However, support for covalent protein modification was obtained from phenol extraction of reactions containing radiolabeled DOB substrate (Figure 3). Radiation in the phenol layer was quantified by liquid scintillation counting following reaction of 3'-<sup>32</sup>P-1 with excess Pol β. The amount of <sup>32</sup>P retained in the phenol was  $45 \pm 2\%$  after subtraction of the background level of radiation extracted in the absence of protein (Figure 3A). The specificity for the covalent interaction between DOB and Pol β was supported by the absence of <sup>32</sup>P above background in the phenol after incubation of 3'-<sup>32</sup>P-1 with bovine serum albumin or 5'-dRP-containing DNA (3'-<sup>32</sup>P-2) with Pol β (Figure 3A). Evidence for irreversible inhibition by butenedial released from DOB was obtained by preparing the ternary complex in which DOB was tritiated (<sup>3</sup>H-DOB, Figure 3).<sup>15</sup> Extraction of 1 containing <sup>3</sup>H-DOB after reaction with excess Pol β resulted in  $51 \pm 2\%$  of the radiation above background being retained in the phenol layer. Inactivation of Pol β by either pathway (Scheme 3) results in transfer of <sup>3</sup>H from 1 to the phenol, but <sup>32</sup>P transfer requires that DOB still be linked to the

DNA. The difference between the percentage of <sup>3</sup>H and <sup>32</sup>P in the phenol layer suggests that  $\geq 90\%$  of the inhibition results from trapping by DOB, whereas butenedial contributes  $\leq 10\%$ .



**Figure 3.** Determination of covalent trapping of Pol β (1.25 μM) via phenol extraction of reactions containing radiolabeled 1. (A) 3'-<sup>32</sup>P-1 (125 nM). (B) <sup>3</sup>H-1 (125 nM).

Our data suggest that competing reactions in the Pol β active site result in inactivation in  $\sim 25\%$  of the enzyme's encounters with DOB. Efficient Pol β inactivation is important for a number of reasons. For instance, these data suggest that DOB may be the 5'-abasic site of undetermined structure produced in cells upon exposure to H<sub>2</sub>O<sub>2</sub> that are resistant to repair by Pol β.<sup>18</sup> In addition, inhibition of Pol β by DOB may provide a chemical basis for the potent cytotoxicity of antitumor agents such as neocarzinostatin. Finally, Pol β is a potentially important target for mechanism-based inhibitors because it is overexpressed in tumor cells and is an attractive target for adjuvants to DNA-targeted anticancer therapies.<sup>19</sup> The reactivity of DOB suggests an approach for designing irreversible inhibitors that target the lyase site of this enzyme.

**Acknowledgment.** We are grateful to Aaron Jacobs and Jon Szczepanski for their careful reading of the manuscript and for generous support from the National Institute of General Medical Sciences (GM-063028).

**Supporting Information Available:** Procedures for the synthesis of all compounds and all of the other experiments; kinetic plots of irreversible inhibition by 1. This material is available free of charge via the Internet at <http://pubs.acs.org>.

### References

- (1) Kishikawa, H.; Jiang, Y.-P.; Goodisman, J.; Dabrowiak, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 5434.
- (2) Gates, K. S. *Chem. Res. Toxicol.* **2009**, *22*, 1747.
- (3) Hashimoto, M.; Greenberg, M. M.; Kow, Y. W.; Hwang, J.-T.; Cunningham, R. P. *J. Am. Chem. Soc.* **2001**, *123*, 3161.
- (4) Szczepanski, J. T.; Jacobs, A. C.; Majumdar, A.; Greenberg, M. M. *J. Am. Chem. Soc.* **2009**, *131*, 11132.
- (5) Guan, L.; Greenberg, M. M. *J. Am. Chem. Soc.* **2009**, *131*, 15225.
- (6) Szczepanski, J. T.; Jacobs, A. C.; Greenberg, M. M. *J. Am. Chem. Soc.* **2008**, *130*, 9646.
- (7) Szczepanski, J.; Jacobs, A. C.; Van Houten, B.; Greenberg, M. M. *Biochemistry* **2009**, *48*, 7565.
- (8) Goldberg, I. H. *Acc. Chem. Res.* **1991**, *24*, 191.
- (9) Chen, B.; Bohnert, T.; Zhou, X.; Dedon, P. C. *Chem. Res. Toxicol.* **2004**, *17*, 1406.
- (10) Chen, B.; Vu, C. C.; Byrns, M. C.; Dedon, P. C.; Peterson, L. A. *Chem. Res. Toxicol.* **2006**, *19*, 982.
- (11) Matsumoto, Y.; Kim, K. *Science* **1995**, *269*, 699.
- (12) Friedberg, E. C.; Walker, G. C.; Siede, W.; Wood, R. D.; Schultz, R. A.; Ellenberger, T. *DNA Repair and Mutagenesis*, 2nd ed.; ASM Press: Washington, DC, 2006.
- (13) Prasad, R.; Beard, W. A.; Strauss, P. S.; Wilson, S. H. *J. Biol. Chem.* **1998**, *273*, 15263.
- (14) Kodama, T.; Greenberg, M. M. *J. Org. Chem.* **2005**, *70*, 9916.
- (15) See the Supporting Information.
- (16) Silverman, R. B. *The Organic Chemistry of Enzyme-Catalyzed Reactions*; Academic Press: San Diego, CA, 2000.
- (17) DeMott, M. S.; Beyret, E.; Wong, D.; Bales, B. C.; Hwang, J.-T.; Greenberg, M. M.; Demple, B. *J. Biol. Chem.* **2002**, *277*, 7637.
- (18) Nakamura, J.; La, D. K.; Swenberg, J. A. *J. Biol. Chem.* **2000**, *275*, 5323.
- (19) Gao, Z.; Maloney, D. J.; Dedkova, L. M.; Hecht, S. M. *Bioorg. Med. Chem.* **2008**, *16*, 4331.

JA101372C